Obesity Clinical Trial
— FiLMEDOfficial title:
Food is Medicine vs Lifestyle Medicine: A Community Based Pragmatic Randomized Control Trial for Patients With Cardiovascular Kidney Metabolic (CKM) Syndrome
The investigators are piloting a 3 month community-based lifestyle medicine program that incorporates experiences and education in urban agriculture, nutrition, culinary arts, and physical fitness to test the hypothesis whether this improves clinical and socio-behavioral outcomes of participants with Cardiovascular Kidney Metabolic (CKM) syndrome (high blood pressure, diabetes, high cholesterol, heart disease, and obesity) in comparison to the current medical care model (usual care) or providing healthy produce (medically tailored groceries).
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | May 2, 2025 |
Est. primary completion date | December 2, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Cardiovascular Kidney Metabolic (CKM) syndrome as described by the American Heart Association (AHA) 1. Stage 1 Metabolic Syndrome: Excess and/or dysfunctional adiposity - overweight/obesity - BMI =25 kg/m2 (or =23 kg/m2 if Asian ancestry) - abdominal obesity - Waist circumference =88/102 cm in women/men (or if Asian ancestry, =80/90 cm in women/men) and/or - dysfunctional adipose tissue - Fasting blood glucose =100-124 mg/dL or HbA1c between 5.7% and 6.4%* - without the presence of other metabolic risk factors or chronic kidney disease (CKD) 2. Stage 2 Metabolic Syndrome: Metabolic risk factors and CKD - hypertriglyceridemia =135 mg/dL - hypertension - metabolic syndrome (MetS†) - waist circumference =88 cm for women and =102 cm for men (if Asian ancestry, =80 cm for women and =90 cm for men) - high-density cholesterol <40 mg/dL for men and <50 mg/dL for women - triglycerides =150 mg/dL - elevated blood pressure (BP) - systolic blood pressure =130 mm Hg and/or diastolic blood pressure =80 mm Hg and/or use of antihypertensive medications - fasting blood glucose =100 mg/dL - Diabetes (HbA1c > 6.5%) - CKD stage 1-3b 3. Stage 3 Subclinical cardiovascular disease (CVD) in CKM - Risk equivalents of subclinical CVD- High predicted 10-y CVD risk 4. Stage 4 Clinical CVD in CKM - Clinical CVD (coronary heart disease, heart failure, stroke, peripheral artery disease, atrial fibrillation) among individuals with excess/dysfunctional adiposity, other metabolic risk factors, 2. Electronic access to MyDataHelps platform either through an internet connected device like a personal computer, Ipad, or their personal phone and consent to its use 3. Must be patient of the NJ Family Practice Center at Rutgers Health/University Hospital Exclusion Criteria: 1. Cardiovascular and Pulmonary Conditions - acute coronary syndrome with coronary artery bypass grafting in the past 3 months - uncontrolled hypertension with systolic BP > 160 or diastolic BP > 100 - heart failure American College of Cardiology (ACC)/AHA Stage C and New York Heart Association (NYHA) > class II - life threatening or uncontrolled arrhythmia - hemodynamically relevant valvular heart disease - infiltrative heart disease including cardiac amyloidosis, sarcoidosis, Fabry's disease - genetic hypertrophic cardiomyopathy - significant pericardial disease - clinically significant congenital heart disease that may be cause of symptoms - significant anemia (hemoglobin <9) - severe chronic obstructive pulmonary disease (oxygen or steroid dependent) - severe restrictive pulmonary disease 2. Mental and Psychological Conditions - active suicidal behavior - substantial depressive symptoms. Antidepressant drugs are allowed if the dose has been stable for 3 months - uncontrolled major psychiatric illness (schizophrenia, bipolar, dementia) - history of drug or alcohol abuse or dependency within the past 12 months - history of medical noncompliance - Intellectual disability resulting in inability to make adult decisions 3. Musculoskeletal conditions - debility resulting in limited unassisted ambulation (being unable to walk 300 meters) - inability to perform activities of daily living unassisted 4. Other Major Organ System Conditions - very high-risk CKD (Stage 4 or 5 CKD or very high risk per Kidney Disease Improving Global Outcomes (KDIGO) classification) - significant hepatic dysfunction - untreated hypothyroidism or hyperthyroidism - cerebrovascular accident within past 6 months with functional residual deficits - clinically relevant neuromuscular disease - cancer or terminal illness with life expectancy < 3 years - pregnant or may become pregnant in the next 6 months - prior major organ transplant or intent to transplant (on the transplant list) 5. Administrative - participant in diabetes, nutrition, or weight research intervention in last 12 months - another family member or household member is a study participant. Only one member of each household may take part in this study. - individuals who have started treatment with a class of medications known as GLP-1 within 120 days of the program start - individuals who have undergone bariatric surgery. - participants without smartphone or web access - individuals who are not proficient in English to a level that would allow for unassisted understanding of study materials and informed consent documentation, as well as effective communication with the research team - individuals currently facing acute unresolved health-related social needs, including but not limited to, unstable housing, lack of reliable transportation, and unemployment - These conditions are considered exclusion criteria due to the potential for it to significantly impact their ability to participate consistently in the study. It can affect the individual's ability to adhere to study protocols, attend follow-up appointments, or impact the generalizability of the study findings. The investigators recognize the importance of addressing these social determinants of health, typically in clinical practice the investigators focus on helping the patient stabilize and resolve health related social needs prior to engaging in a comprehensive therapeutic lifestyle change program. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Rutgers, The State University of New Jersey | Ethos Farm to Health |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Hemoglobin A1C | Measure of glycosylated hemoglobin and diagnostic test for diabetes | 12 weeks after start of intervention | |
Other | Maximum Oxygen Uptake (VO2 Max) | Estimated amount of oxygen uptake possible measured by the YMCA step test. | 12 weeks after start of intervention | |
Other | Total Body Strength as measured by the Isometric Mid-Thigh Pull | Quantitative test of total body strength using an instrumented dead lift technique measured in Newtons of force per kilogram of body weight. | 12 weeks after start of intervention | |
Other | Waist Circumference | a surrogate measure of visceral adiposity and one component of metabolic syndrome | 12 weeks after start of intervention | |
Other | Waist to Hip Ratio | waist circumference measurement divided by the hip circumference measurement. Ratio used to assess non-communicable disease risk | 12 weeks after intervention start | |
Other | Low-Density Lipoprotein Cholesterol (LDL-C) | diagnostic laboratory test assessing low-density lipoprotein cholesterol concentration that correlates with cardiovascular disease risk | 12 weeks after intervention start | |
Other | Blood Pressure | Measurement of arterial wall pressure and risk factor for cardiovascular disease | 12 weeks after intervention start | |
Other | Grip Strength | A simple and reliable measurement of maximum voluntary muscle strength derived from combined contraction of extrinsic and intrinsic hand muscles | 12 weeks after intervention start | |
Other | Body Weight | The mass or quantity of heaviness of an individual, expressed by units of pounds or kilograms | 12 weeks after intervention start | |
Other | Perceived Program Impact | Assessed using "Most Significant Change" tool. It is a qualitative survey tool that assesses an individual's perspective on what caused the most significant change associated with an intervention and why. | 12 weeks after intervention start | |
Other | Non High-Density Lipoprotein Cholesterol (Non-HDL-C) | measure of all atherogenic lipoproteins and cholesterol, including low-density lipoprotein (LDL) but excludes high density lipoprotein (HDL) | 12 weeks after intervention start | |
Primary | Disease reversal | Reduction of disease measures below the threshold for diagnosing the target disease/condition with an absence of medications or procedures known to affect those measures. | 12 weeks after start of intervention | |
Primary | Medication reduction | A decrease in the prescribed dose to the next appropriate dose of a specific agent for a specific condition | 12 weeks after start of intervention | |
Secondary | Food Security | Defined as access by all members, at all times to have enough food for an active, healthy life | 12 weeks after start of intervention | |
Secondary | Diet Quality | Diet quality is broadly defined as a dietary pattern or an indicator of variety across key food groups relative to those recommended in dietary guidelines. Diet quality is objectively measured using the Healthy Eating Index (HEI) 2020 | 12 weeks after start of intervention | |
Secondary | Culinary Attitudes and Behaviors | Assessed using the "Cooking With A Chef" survey instrument which consists of 8 scales assessing: 1. availability and accessibility of fruits and vegetables (AAFV), 2. cooking attitudes (CA) 3. cooking behaviors (CB), 4. produce consumption self efficacy (SEPC) , 5. cooking self-efficacy (SEC), 6. self-efficacy for using basic cooking techniques (SECT) and 7. self-efficacy for using fruit, vegetables, and seasonings (SEFVS) 8. knowledge of cooking terms and techniques. | 12 weeks after start of intervention | |
Secondary | Physical Activity | Self-reported and measured duration and intensity of physical activity | 12 weeks after start of intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |